MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.57
-0.43
-3.07%
After Hours: 13.76 +0.19 +1.40% 19:44 01/21 EST
OPEN
13.86
PREV CLOSE
14.00
HIGH
14.41
LOW
13.51
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
56.50
52 WEEK LOW
12.62
MARKET CAP
1.94B
P/E (TTM)
-5.1425
1D
5D
1M
3M
1Y
5Y
Vigilare Wealth Management Buys BTC iShares MSCI USA Min Vol Factor ETF, Coca-Cola Co, Guardant ...
Investment company Vigilare Wealth Management (Current Portfolio) buys BTC iShares MSCI USA Min Vol Factor ETF, Coca-Cola Co, Guardant Health Inc, Linde PLC, Pfizer Inc, sells iShares Russell 2000 ETF, Verizon Communications Inc, First Trust NASDAQ Clean E...
GuruFocus.com · 01/07 22:38
Rock star Growth Puts TG Therapeutics (NASDAQ:TGTX) In A Position To Use Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 01/03 18:59
Putnam Funds Trust Buys Definitive Healthcare Corp, F45 Training Holdings Inc, RBC Bearings ...
Investment company Putnam Funds Trust (Current Portfolio) buys Definitive Healthcare Corp, F45 Training Holdings Inc, RBC Bearings Inc, Cytokinetics Inc, The Beauty Health Co, sells ABM Industries Inc, II-VI Inc, InMode, AdaptHealth Corp, TG Therapeutics I...
GuruFocus.com · 12/18/2021 07:38
BRIEF-TG Therapeutics Announces Data From The UNITY-CLL Phase 3 Trial
reuters.com · 12/14/2021 12:58
BRIEF-TG Therapeutics Announces FDA Acceptance Of Application For Ublituximab As A Treatment For Multiple Sclerosis
reuters.com · 12/14/2021 12:38
TG Therapeutics Highlights ASH Presentation
 TG Therapeutics, Inc. (NASDAQ:TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination of ublituximab, the Company's investigational anti-CD20
Benzinga · 12/14/2021 12:31
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination of ublituximab, the Company’s investigational anti-CD20 m...
GlobeNewswire · 12/14/2021 12:30
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Appl...
GlobeNewswire · 12/14/2021 12:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TGTX. Analyze the recent business situations of TG Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
62.50%Buy
0.00%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average TGTX stock price target is 48.63 with a high estimate of 75.00 and a low estimate of 13.00.
High75.00
Average48.63
Low13.00
Current 13.57
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 291
Institutional Holdings: 116.27M
% Owned: 81.34%
Shares Outstanding: 142.94M
TypeInstitutionsShares
Increased
76
8.00M
New
33
3.03M
Decreased
76
6.51M
Sold Out
44
2.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Weiss
Chief Financial Officer/Treasurer/Secretary
Sean Power
Lead Director/Independent Director
Laurence Charney
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
William Kennedy
Independent Director
Sagar Lonial
No Data
About TGTX
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.